Abstract Breast cancer is the most common cause of cancer amongst women and is the seventh highest cause of death in this population in the United States. Statistics indicate that minority and underserved populations have worse overall survival from breast cancer. Clinical data from our laboratory have shown that African American and Latino breast cancer patients with HER2/neu overexpression and high pAKT have poor outcomes. In vitro data on breast cancer cells have shown that Cyclin D1 is up-regulated by the PI3K/AKT pathway, while the FOXO1A transcription factor is down-regulated. Hence, the purpose of our current study was to evaluate clinical correlation between pAKT, Cyclin D1, and FOXO1A in tissues from the same patient. We used the same cohort of patients from our previous study. Immunohistochemistry was performed on paraffin tissues from African American and Latino women with breast cancer. Results indicate that patients with HER2/neu overexpression were likely to be Cyclin D1 positive. In addition, those with high pAKT were also Cyclin D1 positive, thus indicating that HER2/neu overexpression might be associated with increase in Cyclin D1 and pAKT. Interestingly, breast tumors with high pAKT and low FOXO1A were also Cyclin D1 positive. In summary, immunohistochemical analysis and subsequent correlation of biomarkers associated with the HER2-PI3/AKT pathway, that include pAKT, Cyclin D1 and FOXO1 may provide better assessment of clinical outcome of breast cancer patients and therefore better target therapies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3751.